Report Highlights

Chlorhexidine Gluconate Wipes in the U.S.: Market Overview

The U.S. chlorhexidine gluconate (CHG) wipes market is valued at USD 412 million in 2024 and is concentrated in acute-care hospitals, ambulatory surgical centers, and long-term care facilities. Demand originates from pre-operative skin antisepsis and daily patient bathing protocols codified in CDC and Joint Commission infection prevention guidance. Private manufacturers, including Sage Products, Medline Industries, and Becton Dickinson, supply most products, while government sets the clinical protocols that define volume.

Policy has shaped the market's current form more than product innovation has. CDC infection prevention guidance on catheter-related and surgical site infections, combined with Medicare Conditions of Participation administered by the Centers for Medicare and Medicaid Services (CMS), moved CHG from a surgical scrub into routine inpatient use. Private firms have led on formulation and distribution, while the federal payer has led on adoption.

Policy-Driven Growth in U.S. Chlorhexidine Gluconate Wipes

The Hospital-Acquired Condition Reduction Program, created under Section 3008 of the Patient Protection and Affordable Care Act, is the strongest demand driver. CMS reduces Medicare payments by 1% for hospitals in the worst-performing quartile on hospital-acquired conditions, including central line-associated bloodstream infections tracked through the CDC's National Healthcare Safety Network. CHG bathing is a core element of hospital prevention bundles, so facilities buy CHG wipes to protect payment rates.

The Hospital Inpatient Quality Reporting Program and the Hospital Value-Based Purchasing Program, established under Section 3001 of the Affordable Care Act, reinforce the same mechanism. Hospitals that fail to report quality data face a two-percentage-point reduction to their annual payment update, while Value-Based Purchasing withholds 2% of base operating payments and redistributes them by performance score. Both programs convert infection outcomes into direct revenue exposure, so CHG wipe budgets are set against compliance targets rather than discretionary spend.

Regulatory Barriers and Compliance Costs for CHG Wipes

CHG wipes are regulated by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act, with the applicable pathway depending on labeled claims. Products with antisepsis claims for healthcare use require a 510(k) premarket notification, and the FDA's review goal is 90 FDA review days under the Medical Device User Fee Amendments. Any change to substrate or concentration restarts the review clock, which delays new product launches by several months.

Hospital procurement adds a second layer of cost. Joint Commission infection prevention standards and Veterans Health Administration national formulary listings require approved product records, so a formulation change triggers a 60-to-90-day pharmacy and infection control review at each facility. Section 301 tariffs administered by U.S. Customs and Border Protection also raise landed costs on Chinese-origin nonwoven substrates, compressing margins for importers.

Policy-Created Opportunities in U.S. Chlorhexidine Gluconate Wipes

The Department of Veterans Affairs' national formulary and General Services Administration Federal Supply Schedule Group 65 contracts create a federal procurement channel for CHG wipes across roughly 170 VA medical centers. Suppliers holding Schedule contracts gain direct access to standardized, multi-year demand that is insulated from commercial price competition. Manufacturers with FDA-cleared, domestically packaged products are best positioned to win these awards.

The Skilled Nursing Facility Quality Reporting Program requires Medicare-certified nursing homes to report infection-related quality measures. This creates demand for single-patient CHG wipes outside the hospital setting, where daily bathing protocols have historically been inconsistent. Suppliers that develop long-term care packaging and staff training materials will capture this shift as facilities align with federal reporting requirements.

Market at a Glance

Leading Market Participants

• Sage Products
• Medline Industries
• Becton Dickinson
• Ecolab
• Cardinal Health
• 3M
• Clorox Healthcare
• Mölnlycke Health Care
• STERIS
• Diversey

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the FDA's Center for Devices and Radiological Health for CHG wipes classified as medical devices. Premarket notification requirements sit under 21 CFR Part 807, while labeling falls under 21 CFR Part 801 and Medical Device Reporting under 21 CFR Part 803. Manufacturers must also comply with the Quality Management System Regulation under 21 CFR Part 820, which aligns with ISO 13485 and takes effect on February 2, 2026.

Upcoming changes include reauthorization of the Medical Device User Fee Amendments (MDUFA V), which expires on September 30, 2027, and finalization of the FDA's Healthcare Antiseptic Drug Products monograph, which remains unresolved. Compared with regional peers, the U.S. framework offers a faster 510(k) pathway than Canada's Medical Device Licence process under the Food and Drugs Act, but a slower monograph finalization. The European Union's Regulation (EU) 2017/745 requires CE marking through notified bodies, making U.S. clearance comparatively more predictable for domestic suppliers.

Long-Term Policy Outlook for Chlorhexidine Gluconate Wipes in the U.S.

By 2032, the HAC Reduction Program and Hospital Value-Based Purchasing will remain the primary demand drivers, with CMS annual IPPS rulemaking expanding the infection measures tied to payment. Hospitals will treat CHG wipes as a compliance input rather than a commodity, which shifts purchasing toward suppliers with documented clinical data and stable supply chains. Market growth will concentrate in facilities that report the most infection measures.

The finalized FDA healthcare antiseptic monograph and MDUFA V outcomes will set the regulatory baseline for the next decade. Section 301 tariff exposure will continue to favor manufacturers with domestic or nearshored substrate production. By 2032, the Skilled Nursing Facility Quality Reporting Program will drive the second major expansion of demand, moving CHG bathing from acute hospitals into long-term care.